Abstract
Cardiovascular disease is the major cause of premature death in modern society, and its impact is increasing due to rising rates of obesity and type 2diabetes. Clinical studies based on targeting metabolic abnormalities and biomarkers demonstrate significant benefits, but always an element of disease remains which is resistant to treatment. Recent evidence has strongly implicated an early interaction of atherogenic lipoproteins with vascular matrix proteoglycans as the initiating step in atherogenesis. Expert commentary has pointed to the need for vascular directed therapies to provide reductions in the residual disease component. We propose that the regulation of synthesis and thus structure of glycosaminoglycans on proteoglycans provides a potential pathway to this reduction. We review existing evidence that the vascular synthesis of glycosaminoglycan chains can be regulated in a manner which reduces lipoprotein binding and the potential application of this strategy to attenuation of the current cardiovascular disease pandemic.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 21 October 2003; received after revision 16 December 2003; accepted 29 December 2003
Rights and permissions
About this article
Cite this article
Ballinger, M.L., Nigro, J., Frontanilla, K.V. et al. Regulation of glycosaminoglycan structure and atherogenesis. CMLS, Cell. Mol. Life Sci. 61, 1296–1306 (2004). https://doi.org/10.1007/s00018-004-3389-4
Issue Date:
DOI: https://doi.org/10.1007/s00018-004-3389-4